Genmab ROE - Return on Equity 2010-2025 | GNMSF

Genmab return on equity for the quarter ending March 31, 2025 was 23.28.

  • Genmab average return on equity for 2024 was 18.33, a 9.17% increase from 2023.
  • Genmab average return on equity for 2023 was 16.79, a 7.19% increase from 2022.
  • Genmab average return on equity for 2022 was 18.09, a 0.28% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Genmab ROE - Return on Equity 2010-2025 | GNMSF

  • Genmab average return on equity for 2024 was 18.33, a 9.17% increase from 2023.
  • Genmab average return on equity for 2023 was 16.79, a 7.19% increase from 2022.
  • Genmab average return on equity for 2022 was 18.09, a 0.28% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.